Other Pharmaceuticals

17 posts

Januvia MDL Established

By Buck Daniel May 1, 2014 – The judge managing the diabetes drug MDL has filed several orders shaping the next steps in the litigation. On Oct. 15, 2013, Judge Lloyd D. George filed an order scheduling a hearing on transferring several new cases to drugs Januvia, Byetta and Victoza […]

Supreme Court to Take Different Look at Generic Drug Manufacturer Liability

By Buck Daniel March 20, 2013 – Two years ago, the Supreme Court severely limited the conditions under which consumers could sue generic drug manufacturers. The Pliva v. Mensing decision stated that generic manufacturers do not have control over a drug’s warning label content due to FDA regulations; and therefore, […]

Affymax and Takeda Institute a Recall of OMONTYS

Posted by Buck Daniel February 25, 2013 – On February 23rd, Affymax and Takeda instituted a recall of OMONTYS following serious adverse reactions, including life threatening and fatal events. Omontys is used to treat anemia associated with chronic kidney disease for patients on dialysis. Anemia, in which the body is […]

Bayer Warns Shareholders of Yaz Settlement Costs

Posted by Buck Daniel September 6, 2012 – Bayer recently informed its investors of the potential costs that will be necessary to settle outstanding lawsuits regarding its birth control medication, Yaz. The company admits it faces no fewer than 12,325 lawsuits regarding the higher risks associated with its product. Nearly […]

Diabetes Drugs Linked to a Higher Risk of Macular Edema

June 12, 2012 – A ten-year study recently concluded that thiazolidinedione drugs, such as Avandia and Actos, may increase the risk of macular edema, a serious eye condition that can lead to blindness. It noted that the incidence of macular edema in studied patients on these drugs was more than […]

Drugs & Devices: How Big Pharma Puts Patients at Risk

June 1, 2012 – American Association for Justice Trial Magazine June 2012 Drugs & Devices: How Big Pharma Puts Patients at Risk “Bad Actos” by Howard L. Nations and John M. Restaino “The safety of Actos, an oral diabetes drug that increases the body’s sensitivity to insulin, has been increasingly […]

MedWatch – Zithromax (azithromycin): FDA Releases Statement on Risk of Cardiovascular Death

By Amber Stanford May 26, 2012 – The FDA has recently recognized a new study released in the issue May 17, 2012 of the New England Journal of Medicine that reports a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a […]